Dianthus Therapeutics Stock Eyes 79% Upside with $145 Price Target
Trevor Allred at Oppenheimer set a $145 price target for Dianthus Therapeutics, implying a 79.3% upside from the current $80.68 share price. The stock has rallied 13-fold over two years alongside volume surges and today’s 23.7% gain to highs near $84.86.
1. Analyst Price Target Update
Oppenheimer analyst Trevor Allred raised the price target for Dianthus Therapeutics to $145, indicating a 79.3% potential upside from the current share price. This forecast underscores confidence in the firm’s strategic direction and growth prospects.
2. Recent Stock Performance
Shares of Dianthus Therapeutics have climbed 13-fold over the past two years, driven by positive clinical progress and heightened investor interest. Today’s trading saw a 23.7% jump to a high of $84.86 on above-average volume, marking the stock’s highest intraday level in a year.
3. Pipeline Advancement Details
The company’s experimental treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) has advanced through key clinical milestones, fueling optimism about future approvals. Positive data readouts have bolstered expectations for late-stage trials and potential commercialization.
4. Market Metrics and Volatility
Dianthus Therapeutics holds a market capitalization of approximately $2.92 billion with daily trading volumes around 2.9 million shares. The stock has ranged between $13.37 and $84.86 over the past year, illustrating significant volatility tied to development news.